This observation underlines the importance of assessing PI3K pathway activation in T-ALL patients rather than just PTEN deletions/mutations, for a better evaluation of patient outcome or possible therapeutic intervention with pathway modulators. This evidence concerns the gene PIK3CG and acute lymphoblastic leukemia.